Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Nebraska Genzyme |
---|---|
Information provided by: | University of Nebraska |
ClinicalTrials.gov Identifier: | NCT00564538 |
The purpose of this study is to compare kidney function, long term patient and graft survival, and incidence of acute rejection in liver transplant recipients between one group receiving thymoglobulin induction and delayed initiation of tacrolimus and another group of liver transplant recipients having immediate administration of tacrolimus without any induction immunosuppression.
Condition | Intervention | Phase |
---|---|---|
Liver Transplantation Liver Disease Immunosuppression |
Drug: anti-thymocyte globulin (rabbit) Drug: tacrolimus |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Study Comparing Thymoglobulin to Tacrolimus in Liver Transplant and Impact on Renal Function |
Estimated Enrollment: | 100 |
Study Start Date: | December 2007 |
Estimated Study Completion Date: | December 2009 |
Arms | Assigned Interventions |
---|---|
1: Experimental
Patients in arm 1 will receive induction with thymoglobulin at time of transplant with delayed initiation of tacrolimus
|
Drug: anti-thymocyte globulin (rabbit)
1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
|
2: Active Comparator
patients in arm 2 will not receive thymo induction at time of transplant and will have immediate initiation of tacrolimus
|
Drug: tacrolimus
Tacrolimus will be administered orally on post op day #1 as per standard of care.
|
Renal insufficiency following liver transplantation in adult recipients is a major cause of morbidity and a major contributor to mortality. One of the key factors contributing to this renal dysfunction is the use of calcineurin inhibitors. There is some evidence to suggest that the first 7-10 days following liver transplantation are crucial in terms of renal function and the ability to avoid the use of nephrotoxic agents such as calcineurin inhibitors may have a significant impact on long-term outcome.
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Nebraska | |
University of Nebraska Medical Center | |
Omaha, Nebraska, United States, 68198 |
Principal Investigator: | Wendy Grant, MD | University of Nebraska |
Study ID Numbers: | 424-07 |
Study First Received: | November 27, 2007 |
Last Updated: | November 27, 2007 |
ClinicalTrials.gov Identifier: | NCT00564538 |
Health Authority: | United States: Institutional Review Board |
liver transplant |
Antilymphocyte Serum Liver Diseases Digestive System Diseases Tacrolimus |
Immunologic Factors Physiological Effects of Drugs Immunosuppressive Agents Pharmacologic Actions |